Guidance
MCV 5-dose 2-Pager
This two-page brief summarizes the rationale, evidence, and implementation considerations for transitioning from 10-dose to 5-dose measles-containing vaccine (MCV) vials for routine immunization. Designed for EPI managers, NITAGs, and immunization partners, it outlines how fewer-dose vials can reduce missed opportunities for vaccination, improve coverage, and support routine immunization strengthening. The brief highlights global evidence and country experiences, key considerations for assessing country fit, funding and implementation implications, and practical next steps for planning a switch to the 5-dose presentation.
Authors
Languages
- English
Publication year
2026
Type
Guidance
Categories
- Vaccines & delivery devices
Diseases
- Measles
- Rubella
Tags
- Vaccine presentation and packaging
MCV5 PHASE 1
This resource appears in the following Hot Topic page:
The resource is included in the following table:
| Title | Author | Year | Type | Language |
|---|---|---|---|---|
| MCV 5-dose Vial Assessment Tool | Linksbridge | 2026 | Tool | English, French |
| MCV 5-dose Research and Resources | Linksbridge | 2022 | Report | English |
| Measles and Measles-Rubella (MR) Vaccine Five-Dose Vial Presentation - Fact Sheet 2022 - 2023 | UNICEF, World Health Organization (WHO) | 2022 | Guidance | English |
| Experiences with the MCV 5-dose Switch from Africa’s EPI | UNICEF | 2024 | Case study | English |
| How To Use: Step-by-Step Instructions for the MCV 5-dose National Impact Assessment Tool | Linksbridge | 2025 | User guide | English |
| MCV 5-dose Option Overview | Linksbridge | 2026 | Guidance | English |
| MCV 5-dose 2-Pager | Linksbridge | 2026 | Guidance | English |
